These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35872580)

  • 1. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 2. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
    Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
    Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
    [No Abstract]   [Full Text] [Related]  

  • 4. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
    Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
    Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
    Chen L; Wang J; Wang Z
    Ann Hematol; 2022 Nov; 101(11):2461-2470. PubMed ID: 36094533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China.
    Ma H; Zhang R; Zhang L; Wei A; Zhao X; Yang Y; Liu W; Li Z; Qin M; Wang T
    Ann Hematol; 2020 Oct; 99(10):2255-2263. PubMed ID: 32766934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
    Huang Z; Xie J
    Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.
    Wang Y; Huang W; Hu L; Cen X; Li L; Wang J; Shen J; Wei N; Wang Z
    Blood; 2015 Nov; 126(19):2186-92. PubMed ID: 26289641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis].
    Wang Y; Huang W; Wei N; Zeng X; Zhang J; Wang J; Wu L; Fu L; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):901-4. PubMed ID: 25339326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
    Yan WL; Yang SL; Zhao FY; Xu XJ
    J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis.
    Ge J; Zhang Q; Ma H; Wang D; Zhao Y; Zhu T; Wang W; Zhou C; Wei A; Lian H; Qin M; Yang J; Li Z; Wang T; Zhang R
    Haematologica; 2024 Feb; 109(2):458-465. PubMed ID: 37470145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
    Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
    Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
    Xu Y; Li W; Gan J; He X; Huang X
    Ann Hematol; 2023 Dec; 102(12):3325-3333. PubMed ID: 37787838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
    Zhang Q; Zhao YZ; Ma HH; Wang D; Cui L; Li WJ; Wei A; Wang CJ; Wang TY; Li ZG; Zhang R
    Blood; 2022 Jun; 139(24):3493-3504. PubMed ID: 35344583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphoma-based therapy for refractory or relapsed Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in children.
    Cheng CN; Chu WY; Chang KC; Chen JS
    J Formos Med Assoc; 2022 Nov; 121(11):2351-2355. PubMed ID: 35123848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Treatment of Relapsed Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report.
    Pi Y; Wang J; Wang Z
    Infect Drug Resist; 2022; 15():3751-3756. PubMed ID: 35859915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.
    Liu P; Pan X; Chen C; Niu T; Shuai X; Wang J; Chen X; Liu J; Guo Y; Xie L; Wu Y; Liu Y; Liu T
    Blood; 2020 Mar; 135(11):826-833. PubMed ID: 31914172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.